Seeking Alpha

Amarin (AMRN +3.7%) is very close to receiving a long-sought patent on its lead drug candidate,...

Amarin (AMRN +3.7%) is very close to receiving a long-sought patent on its lead drug candidate, AMR101, after the USPTO issues a Notice of Allowance supporting the use of the fish-oil heart pill in patients with high triglycerides. A Notice of Allowance is typically issued after regulators decide that a patent can be granted from an application. Next up is an FDA decision on AMR101, expected this month. (PR)
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs